T Barth1, F Zeman2, H Helbig3, M-A Gamulescu3. 1. Department of Ophthalmology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. teresa.barth@ukr.de. 2. Centre for Clinical Studies (ZKS), University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 3. Department of Ophthalmology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Abstract
PURPOSE: To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. METHODS: Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed. RESULTS: Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1-9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6-40 months). BCVA improved in eight eyes (mean Δ +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Δ -4.3 lines). CONCLUSIONS: CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.
PURPOSE: To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. METHODS: Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed. RESULTS: Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1-9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6-40 months). BCVA improved in eight eyes (mean Δ +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Δ -4.3 lines). CONCLUSIONS: CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.
Authors: J Fernando Arevalo; Alfredo Adan; Maria H Berrocal; Juan V Espinoza; Mauricio Maia; Lihteh Wu; Jose A Roca; Hugo Quiroz-Mercado; Jose M Ruiz-Moreno; Martin A Serrano Journal: Retina Date: 2011-02 Impact factor: 4.256
Authors: Angela M Carneiro; Rufino M Silva; Maria J Veludo; Augusto Barbosa; José M Ruiz-Moreno; Manuel S Falcão; Elisete M Brandão; Fernando M Falcão-Reis Journal: Ophthalmologica Date: 2010-09-24 Impact factor: 3.250
Authors: Theresa G Leung; Ahmadreza Moradi; Dianna Liu; Quan D Nguyen; James P Dunn; Bryn Burkholder; Nicholas J Butler; Trucian Ostheimer; Jennifer E Thorne Journal: Retina Date: 2014-08 Impact factor: 4.256
Authors: Konstantinos T Tsaousis; Mohamed Nassr; Bharat Kapoor; Vasileios E Konidaris; Straton Tyradellis; Theo Empeslidis Journal: SAGE Open Med Case Rep Date: 2018-05-06
Authors: Soohyun Kim; Jennifer J Kang-Mieler; Wenqiang Liu; Zhe Wang; Glenn Yiu; Leandro B C Teixeira; William F Mieler; Sara M Thomasy Journal: Transl Vis Sci Technol Date: 2020-02-27 Impact factor: 3.283